Economic information and modeling report
Modeling overview
1 evidence topic · 2 sources
Summary: economic modeling and pricing status
No published cost-effectiveness analysis, budget impact model, or health technology assessment of bevacizumab-vikg has been identified. Outlook Therapeutics established a wholesale acquisition cost of $485 per vial for the United States on September 16, 2026, ahead of a planned U.S. commercial launch before the end of calendar 2026, and has stated that LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030.